跳到正文
原文
MedPage Today·· 16 天前精选AI 评分85

PROGRESS试验表明早期TAVR优于临床监测

Upfront TAVR May Be the Way Forward in Moderate Aortic Stenosis, Trial Suggests

AI 导读

PROGRESS试验表明,对于中度主动脉瓣狭窄且至少有一个高风险特征的患者,早期TAVR比临床监测更有效,2年时死亡或心衰事件发生率分别为16.7%和23.9%(HR 0.67,P=0.02)。该研究支持在有高风险特征的中度主动脉瓣狭窄患者中采用TAVR。

推荐理由

研究显示,对于有中度主动脉瓣狭窄且至少有一个高风险特征的患者,早期TAVR比临床监测更有效,可降低死亡和心衰事件风险。

正文 · 原文

— First randomized study to evaluate TAVR versus clinical surveillance in moderate AS

by Nicole Lou, Senior Staff Writer, MedPage Today

November 3, 2026 • 4 min read

Upfront transcatheter aortic valve replacement (TAVR) was more protective against death and heart failure events compared with clinical surveillance among patients with moderate aortic stenosis (AS) with at least one at-risk feature, the randomized PROGRESS trial showed.

At 2 years, a composite endpoint of death from any cause or a heart failure event occurred in 16.7% of patients in the upfront TAVR group versus 23.9% of those in the clinical surveillance group (HR 0.67, 95% CI 0.48-0.93, P=0.02 for superiority), reported Philippe Généreux, MD, of the Gagnon Cardiovascular Institute at Morristown Medical Center in New Jersey, during the Transcatheter Cardiovascular Therapeutics annual conference, hosted by the Cardiovascular Research Foundation.

In addition, TAVR with the balloon-expandable Sapien 3 platform had a safety event rate of 5.9% at 30 days, which was well under the prespecified 13.7% performance goal, and the bulk of events were hospitalizations for device- or procedure-related complications (5.6%).

The study was simultaneously published in the New England Journal of Medicine.

"Moderate AS is not benign, and these patients would benefit from earlier referral to a valve clinic for comprehensive evaluation to establish the optimal management strategy," Généreux concluded. "Rather than waiting for progression to severe AS, PROGRESS supports TAVR for patients with moderate AS and at-risk features."

Importantly, the trial has follow-up planned for 10 years. In the meantime, Généreux said that the PROGRESS trial has already identified the "optimal time" for intervention in AS considering the balance of safety and efficacy.

Among the clinical surveillance patients who started out with moderate AS, 57.4% eventually underwent a delayed aortic valve replacement (AVR) by 24 months. Of these patients, over 80% had progressed to severe AS.

Meanwhile, the TAVR arm showed the "best hemodynamics that we ever saw" with the Sapien valve, Généreux reported, citing the effective orifice areas, mean gradients, and minimal paravalvular leaks achieved. "The future will tell, but I strongly believe based on the data today ... [that] this is the optimal timing of intervention to ensure optimal treatment for a patient given that we can treat a second time."

"This disease progressed faster than [we] expected," he stressed. "You need to follow these patients. You cannot abandon them."

During a press conference, panelist Pinak Shah, MD, of Mass General Brigham in Boston, called the trial a "truly practice-changing study" that "really underscores the importance of close follow-up and the fact that AS is not a benign disease."

The results also suggest a drastic widening of the pool of TAVR candidates.

A large registry study, also by Généreux and colleagues, recently showed that patients with moderate AS outnumber those with severe AS by nearly 2:1, and over a quarter of those with moderate AS in this study progressed to severe AS by 2 years.

Ultimately, Généreux argued for doing away with the dichotomy of moderate versus severe AS altogether and moving towards intervention on "clinically significant" AS instead.

For their trial, the investigators sought participants who were at least 65 years old with moderate AS plus at least one at-risk feature. The majority were recruited from the U.S. (87.1%), with a minority coming from sites in Japan, Australia, the Netherlands, Canada, and Switzerland.

Out of 1,294 patients screened, 744 were randomized 1:1 to transfemoral TAVR or once-yearly clinical surveillance from October 2021 to January 2024. Mean age was 78 years, and 39% were women. The Society of Thoracic Surgery risk score was about 3.0%, and fewer than half of patients were deemed low risk per the heart team. New York Heart Association class III/IV symptoms were observed in about 35% at baseline. The Kansas City Cardiomyopathy Questionnaire (KCCQ) score was about 64 on average.

The top at-risk features that qualified people for the study were valve-related symptoms (96.4%) and diastolic dysfunction (43.8%).

Généreux reported that 91% of enrolled patients had moderate AS in terms of both moderate aortic valve area (AVA) criteria and peak velocity/mean gradients. The mean AVA was 1.2 cm2, the mean gradient was just over 25 mm Hg, and the peak velocity was 3.3 m/s. About one in four people had an elevated aortic valve calcium score.

The effectiveness endpoint was a composite of death (8.4% vs 7.3%, HR 1.14, 95% CI 0.67-1.93) and heart failure events (10.8% vs 19.0%, HR 0.55, 95% CI 0.37-0.81). Of note, a heart failure event had to meet all three criteria: new or worsening heart failure symptoms, two or more objective indications of new or worsening heart failure (physical, laboratory, imaging, and/or invasive findings), and escalation of heart failure treatment.

Altogether, the number needed to treat for benefit at 2 years was 14 in the trial.

Separately, as a standalone endpoint, heart failure hospitalizations were fewer in the TAVR arm (7.4% vs 14.9%, HR 0.48, 95% CI 0.30-0.77). However, the composite of death, stroke, or heart failure hospitalization did not statistically give TAVR an edge (17.7% vs 23.3%, P=0.07).

As for health status improvement, the mean KCCQ score was 79.6 points in the TAVR arm at 30 days. The proportion of patients alive with an improvement of 10+ points in KCCQ score at 1 and 2 years favored TAVR (39.0% vs 23.2%, P<0.001).

Généreux noted that when it came to delayed AVR in the control arm of the study, KCCQ scores generally dipped before the delayed procedure, followed by a substantial improvement 30 days later.

The incidence rate of new permanent pacemakers was 13.0% with upfront TAVR versus 10.4% with clinical surveillance.

Of note, limiting wider generalizability, PROGRESS had notable exclusion criteria that barred people with unsuitable anatomy for transfemoral TAVR, significant clinical comorbidities, very low ejection fractions, or prior aortic valve replacement or valvuloplasty, among others.

"Certainly, we have to be very careful with patient selection," commented Shah. "For most, the lifetime management is going to be important ... A lot of these patients are probably going to come back for repeat procedures."

来源:MedPage Today · medpagetoday.com